Durect Stock Today
| DRRX Stock | USD 0.79 0.01 1.25% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Durect is trading at 0.79 as of the 26th of February 2025; that is 1.25% down since the beginning of the trading day. The stock's open price was 0.8. Durect has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 1st of June 2024 and ending today, the 26th of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 28th of September 2000 | Category Healthcare | Classification Health Care |
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California. Durect Corp operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 31.04 M outstanding shares of which 809.08 K shares are currently shorted by private and institutional investors with about 8.99 trading days to cover. More on Durect
Moving against Durect Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Durect Stock Highlights
| Thematic Idea | Pharmaceutical Products (View all Themes) | ||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Pharmaceutical Products, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsDurect can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Durect's financial leverage. It provides some insight into what part of Durect's total assets is financed by creditors.
| |||||
Durect (DRRX) is traded on NASDAQ Exchange in USA. It is located in 10240 Bubb Road, Cupertino, CA, United States, 95014-4166 and employs 46 people. Durect is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 24.49 M. Durect conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 31.04 M outstanding shares of which 809.08 K shares are currently shorted by private and institutional investors with about 8.99 trading days to cover.
Durect currently holds about 51.89 M in cash with (34.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23.
Check Durect Probability Of Bankruptcy
Ownership AllocationDurect holds a total of 31.04 Million outstanding shares. Durect shows 10.85 percent of its outstanding shares held by insiders and 22.1 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Durect Ownership Details
Durect Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Accredited Investors Inc | 2024-12-31 | 91.9 K | |
| Citadel Advisors Llc | 2024-09-30 | 74.7 K | |
| Northern Trust Corp | 2024-12-31 | 50.3 K | |
| Silverberg Bernstein Capital Management Llc | 2024-12-31 | 43.4 K | |
| Jane Street Group Llc | 2024-12-31 | 39.2 K | |
| Ubs Group Ag | 2024-12-31 | 32.4 K | |
| International Assets Investment Management, Llc | 2024-09-30 | 27.2 K | |
| Xtx Topco Ltd | 2024-12-31 | 24.5 K | |
| Raymond James & Associates | 2024-09-30 | 22.3 K | |
| Ingalls & Snyder Llc | 2024-12-31 | 1.6 M | |
| Richmond Brothers Inc | 2024-12-31 | 1.3 M |
Durect Historical Income Statement
Durect Stock Against Markets
Durect Corporate Management
| James DVM | CEO, CoFounder | Profile | |
| Jian MBA | Corporate Finance | Profile | |
| Su Yum | Executive Officer | Profile | |
| Norman MD | Chief Officer | Profile | |
| Keith MBA | Commercial Development | Profile | |
| Andrew Miksztal | VP Scientist | Profile |
Additional Tools for Durect Stock Analysis
When running Durect's price analysis, check to measure Durect's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Durect is operating at the current time. Most of Durect's value examination focuses on studying past and present price action to predict the probability of Durect's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Durect's price. Additionally, you may evaluate how the addition of Durect to your portfolios can decrease your overall portfolio volatility.